Patents Assigned to Biotie Therapies Corp.
-
Patent number: 10576148Abstract: The present invention relates to inhibitors of VAP-1 and their use as medicaments in treating fibrotic conditions. Furthermore, the present invention relates to a method of diagnosing a fibrotic condition on the basis of elevated level of soluble VAP-1 or SSAO activity in a bodily fluid, and to a kit for use in said diagnostic method.Type: GrantFiled: September 21, 2017Date of Patent: March 3, 2020Assignees: BIOTIE THERAPIES CORP., THE UNIVERSITY OF BIRMINGHAMInventors: Christopher Weston, Lee Charles Claridge, David Adams, David Smith, Nina Westerlund, Marjo Pihlavisto, Thua Österman
-
Publication number: 20180071388Abstract: The present invention relates to inhibitors of VAP-1 and their use as medicaments in treating fibrotic conditions. Furthermore, the present invention relates to a method of diagnosing a fibrotic condition on the basis of elevated level of soluble VAP-1 or SSAO activity in a bodily fluid, and to a kit for use in said diagnostic method.Type: ApplicationFiled: September 21, 2017Publication date: March 15, 2018Applicants: BIOTIE THERAPIES CORP., THE UNIVERSITY OF BIRMINGHAMInventors: Christopher WESTON, Lee Charles CLARIDGE, David ADAMS, David SMITH, Nina WESTERLUND (DECEASED), Marjo PIHLAVISTO, Thua ÖSTERMAN (DECEASED)
-
Patent number: 9795671Abstract: The present invention relates to inhibitors of VAP-1 and their use as medicaments in treating fibrotic conditions. Furthermore, the present invention relates to a method of diagnosing a fibrotic condition on the basis of elevated level of soluble VAP-1 or SSAO activity in a bodily fluid, and to a kit for use in said diagnostic method.Type: GrantFiled: September 7, 2010Date of Patent: October 24, 2017Assignees: BIOTIE THERAPIES CORP., THE UNIVERSITY OF BIRMINGHAMInventors: Christopher Weston, Lee Charles Claridge, David Adams, David Smith, Nina Westerlund, Max Ole Valdemar Westerlund, Marjo Pihlavisto, Thua Österman, Elina Ainomaija Antikainen
-
Publication number: 20130195883Abstract: The present invention relates to inhibitors of VAP-1 and their use as medicaments in treating fibrotic conditions. Furthermore, the present invention relates to a method of diagnosing a fibrotic condition on the basis of elevated level of soluble VAP-1 or SSAO activity in a bodily fluid, and to a kit for use in said diagnostic method.Type: ApplicationFiled: September 7, 2010Publication date: August 1, 2013Applicants: THE UNIVERSITY OF BIRMINGHAM, BIOTIE THERAPIES CORP.Inventors: Christopher Weston, Lee Charles Claridge, David Adam, David Smith, Nina Westerlund, Marjo Pihlavisto, Thua Österman
-
Publication number: 20120115815Abstract: This invention relates to a method for treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom in an individual, wherein an effective amount of an amine oxidase enzyme inhibitor is administered to said individual. In addition, the invention relates to a method for inhibiting an amine oxidase enzyme or for treatment or prevention of diseases or conditions benefiting from inhibition of an amine oxidase enzyme in an individual, wherein a vitamin B1, its derivative, its precursor or metabolite is administered to said individual. Finally, the invention relates to a food product comprising an amine oxidase enzyme inhibitor in combination with a foodstuff, a food additive comprising an amine oxidase enzyme inhibitor in combination with a liquid, solid or semisolid carrier.Type: ApplicationFiled: January 19, 2012Publication date: May 10, 2012Applicant: BIOTIE THERAPIES CORP.Inventors: Sirpa JALKANEN, Marko SALMI, Markku JALKANEN
-
Patent number: 8142783Abstract: Novel fully human anti-VAP-1 antibodies and fragments thereof are disclosed. Nucleic acids encoding anti-VAP-1 antibodies or fragments thereof, as well as expression vectors and host cells incorporating these nucleic acids for the recombinant expression of anti-VAP-1 antibodies are also given. Pharmaceutical compositions comprising said antibodies and therapeutic uses thereof are also disclosed.Type: GrantFiled: November 5, 2010Date of Patent: March 27, 2012Assignee: Biotie Therapies Corp.Inventors: David John Smith, Petri Vainio, Jari Mikkola, Päivi Vuorio, Jani Vainio
-
Patent number: 8119651Abstract: This invention relates to a method for treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom in an individual, wherein an effective amount of an amine oxidase enzyme inhibitor is administered to said individual. In addition, the invention relates to a method for inhibiting an amine oxidase enzyme or for treatment or prevention of diseases or conditions benefiting from inhibition of an amine oxidase enzyme in an individual, wherein a vitamin B1, its derivative, its precursor or metabolite is administered to said individual. Finally, the invention relates to a food product comprising an amine oxidase enzyme inhibitor in combination with a foodstuff, a food additive comprising an amine oxidase enzyme inhibitor in combination with a liquid, solid or semisolid carrier.Type: GrantFiled: April 1, 2008Date of Patent: February 21, 2012Assignee: Biotie Therapies Corp.Inventors: Sirpa Jalkanen, Marko Salmi, Markku Jalkanen
-
Publication number: 20110251228Abstract: The present invention relates to the Nalmefene hydrochloride dihydrate, methods of manufacturing Nalmefene hydrochloride dihydrate, a pharmaceutical composition comprising Nalmefene hydrochloride dihydrate and a method of treatment comprising administering Nalmefene hydrochloride dehydrate.Type: ApplicationFiled: December 4, 2009Publication date: October 13, 2011Applicants: Biotie Therapies Corp., H. Lundbeck A/SInventors: Heidi Lopez de Diego, Carla de Faveri, Florian Anton Martin Huber
-
Patent number: 7897149Abstract: Novel fully human anti-VAP-1 antibodies and fragments thereof are disclosed. Nucleic acids encoding anti-VAP-1 antibodies or fragments thereof, as well as expression vectors and host cells incorporating these nucleic acids for the recombinant expression of anti-VAP-1 antibodies are also given. Pharmaceutical compositions comprising said antibodies and therapeutic uses thereof are also disclosed.Type: GrantFiled: April 18, 2008Date of Patent: March 1, 2011Assignee: Biotie Therapies Corp.Inventors: David John Smith, Petri Vainio, Jari Mikkola, Päivi Vuorio, Jani Vainio
-
Publication number: 20100261253Abstract: The invention is directed to a novel purified mouse C5-epimerase, fragments thereof, nucleic acids encoding the same and the recombinant production thereof. The invention is also directed to fragments of such epimerase, especially N-terminal fragments that are useful in fusion protein constructs to enhance the activity of recombinantly-produced heterologous epimerase enzymes.Type: ApplicationFiled: July 8, 2008Publication date: October 14, 2010Applicants: BioTie Therapies Corp., Inalco S.p.A.Inventors: Markku Jalkanen, Kamel El Darwish, Ulf Lindahl, Jin-Ping Li
-
Patent number: 7399626Abstract: The invention is directed to a novel purified mouse C5-epimerase, fragments thereof, nucleic acids encoding the same and the recombinant production thereof. The invention is also directed to fragments of such epimerase, especially N-terminal fragments that are useful in fusion protein constructs to enhance the activity of recombinantly-produced heterologous epimerase enzymes.Type: GrantFiled: April 11, 2005Date of Patent: July 15, 2008Assignees: BioTie Therapies Corp., Inalco S.p.A.Inventors: Markku Jalkanen, Kamel El Darwish, Ulf Lindahl, Jin-Ping Li
-
Patent number: 6982286Abstract: The present invention is directed to carbocyclic hydrazino compounds that function as inhibitors of copper-containing amine oxidases commonly known as semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO known as Vascular Adhesion Protein-I (VAP-1). These SSAO inhibitors have therapeutic utility as drugs to treat conditions and diseases including, but not limited to, a number of inflammatory conditions and diseases (in particular chronic inflammatory conditions such as chronic arthritis, inflammatory bowel diseases, and chronic skin dermatoses), diseases related to carbohydrate metabolism and to aberrations in adipocyte differentiation or function and smooth muscle cell function, and vascular diseases. The novel compounds have the general formula: or a pharmaceutically acceptable solvate, hydrate, or salt thereof wherein R1 to R11 are as defined herein.Type: GrantFiled: July 12, 2001Date of Patent: January 3, 2006Assignee: Biotie Therapies Corp.Inventors: David John Smith, Ferenc Fülöp, Marjo Pihlavisto, László Lázár, Sakari Alaranta, Petri Vainio, Zsolt Szakonyi
-
Publication number: 20050181434Abstract: The invention is directed to a novel purified mouse C5-epimerase, fragments thereof, nucleic acids encoding the same and the recombinant production thereof. The invention is also directed to fragments of such epimerase, especially N-terminal fragments that are useful in fusion protein constructs to enhance the activity of recombinantly-produced heterologous epimerase enzymes.Type: ApplicationFiled: April 11, 2005Publication date: August 18, 2005Applicants: BioTie Therapies Corp., Inalco S.p.A.Inventors: Markku Jalkanen, Kamel El Darwish, Ulf Lindahl, Jin-ping Li
-
Patent number: 6887698Abstract: The invention is directed to a novel purified mouse C5-epimerase, fragments thereof, nucleic acids encoding the same and the recombinant production thereof. The invention is also directed to fragments of such epimerase, especially N-terminal fragments that are useful in fusion protein constructs to enhance the activity of recombinantly-produced heterologous epimerase enzymes.Type: GrantFiled: December 7, 2001Date of Patent: May 3, 2005Assignees: Biotie Therapies Corp., Inalco S.p.A.Inventors: Markku Jalkanen, Kamel El Darwish, Ulf Lindahl, Jin-ping Li
-
Patent number: 6764844Abstract: An isolated or recombinant DNA sequence coding for a mammalian, including human, glucuronyl C5-epimerase or a functional derivative thereof capable or converting D-glucuronyl acid (GlcA) to L-iduronic acid (IdoA); a recombinant expression vector comprising such DNA sequence; a host cell transformed with such recombinant expression vector; a process for manufacture of a glucuronyl C5-epimerase or functional derivative thereof capable of coverting GlcA to IdoA, comprising cultivation of a cell-line transformed with such recombinant expression vector; and a glucuronyl C5-epimerase or functional derivative thereof prepared by such process.Type: GrantFiled: October 18, 1999Date of Patent: July 20, 2004Assignee: Biotie Therapies, Corp.Inventors: Ulf Lindahl, Jing-ping Li
-
Patent number: 6624202Abstract: The present invention is directed to hydrazino compounds that function as inhibitors of copper-containing amine oxidases commonly known as semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO known as Vascular Adhesion Protein-1 (VAP-1). These SSAO inhibitors have therapeutic utility as drugs to treat conditions and diseases including, but not limited to, a number of inflammatory conditions and diseases (in particular chronic inflammatory conditions such as chronic arthritis, inflammatory bowel diseases, and chronic skin dermatoses), diseases related to carbohydrate metabolism and to aberrations in adipocyte differentiation or function and smooth muscle cell function, and vascular diseases. The compounds have the general formula: or a pharmaceutically acceptable solvate, hydrate, or salt thereof, wherein R1 to R8 and X are as defined herein.Type: GrantFiled: July 5, 2001Date of Patent: September 23, 2003Assignee: Biotie Therapies Corp.Inventors: David John Smith, Markku Jalkanen, Ferenc Fülöp, László Lázár, Zsolt Szakonyi, Gábor Bernáth
-
Publication number: 20030125360Abstract: The present invention is directed to carbocyclic hydrazino compounds that function as inhibitors of copper-containg amine oxidases commonly known as semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO known as Vascular Adhesion Protein-I (VAP-1). These SSAO inhibitors have therapeutic utility as drugs to treat conditions and diseases including, but not limited to, a number of inflammatory conditions and diseases (in particular chronic inflammatory conditions such as chronic arthritis, inflammatory bowel diseases, and chronic skin dermatoses), diseases related to carbohydrate metabolism and to aberrations in adipocyte differentiation or function and smooth muscle cell function, and vascular diseases.Type: ApplicationFiled: July 12, 2001Publication date: July 3, 2003Applicant: Biotie Therapies Corp.Inventors: David John Smith, Ferenc Fulop, Marjo Pihlavisto, Laszlo Lazar, Sakari Alaranta, Petri Vainio, Zsolt Szakonyi
-
Patent number: 6492344Abstract: Methods are provided for altering levels of syndecan within a cell. The methods include enhancing syndecan expression via administration of growth factors, preventing suppression of syndecan expression via administration of anti-steroid agents, and altering syndecan biochemistry within the cell. The methods are used to induce or maintain cellular differentiation, and to decrease the growth of malignant cells. Application of the methods to the treatment of patients, including humans, is provided. A syndecan enhancer element, novel proteins that activate the enhancer element, non-human transgenic animals comprising this enhancer element linked to a structural gene, and the use of this enhancer element to regulate the expression of syndecan and other genes are also provided. The enhancer element can also be used to target expression of a gene to wound sites.Type: GrantFiled: June 21, 1999Date of Patent: December 10, 2002Assignee: Biotie Therapies Corp.Inventors: Markku Jalkanen, Panu Jaakkola, Tapani Vihinen
-
Publication number: 20020173521Abstract: The present invention is directed to hydrazono compounds that function as inhibitors of copper-containg amine oxidases commonly known as semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO known as Vascular Adhesion Protein-1 (VAP-1). These SSAO inhibitors have therapeutic utility as drugs to treat conditions and diseases including, but not limited to, a number of inflammatory conditions and diseases (in particular chronic inflammatory conditions such as chronic arthritis, inflammatory bowel diseases, and chronic skin dermatoses), diseases related to carbohydrate metabolism and to aberrations in adipocyte differentiation or function and smooth muscle cell function, and vascular diseases.Type: ApplicationFiled: July 5, 2001Publication date: November 21, 2002Applicant: Biotie Therapies Corp.Inventors: David John Smith, Markku Jalkanen, Ferenc Fulop, Lazlo Lazar, Zsolt Szakonyi, Gabor Bernath
-
Publication number: 20020127696Abstract: The invention is directed to a novel purified mouse C5-epimerase, fragments thereof, nucleic acids encoding the same and the recombinant production thereof. The invention is also directed to fragments of such epimerase, especially N-terminal fragments that are useful in fusion protein constructs to enhance the activity of recombinantly-produced heterologous epimerase enzymes.Type: ApplicationFiled: December 7, 2001Publication date: September 12, 2002Applicant: BioTie Therapies Corp.Inventors: Markku Jalkanen, Kamel El Darwish, Ulf Lindahl, Jin-Ping Li